

Silence Therapeutics PLC

13:10 25 Apr 2019

Silence Therapeutics says Iain Ross to return as its chairman and non-executive director with immediate effect

Silence Therapeutics PLC (LON:SLN) shares rose on Thursday following news it has appointed Iain Ross as a non-executive director and its chairman with immediate effect, with the experienced director returning to a role he held from 2005 to 2010.

The AIM-listed group, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, pointed out that Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years.

READ: Silence Therapeutics confirms Dr Rob Quinn as chief financial officer. Currently, it added, he is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma Plc.

Dr. David Horn Solomon, Silence's chief executive officer commented: "Iain brings with him extensive healthcare and governance experience and I am looking forward to working with him to build significant value for shareholders, patients and their caregivers."

Incoming chairman Ross added: "I am delighted to be returning to Silence Therapeutics and I look forward to working with David, the new management team and all stakeholders. With a renewed strategy in place and a return to the clinic imminent I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the Board to deliver on its potential."

Silence also announced the appointment of James Ede-Golightly as a non-executive director, while it said Stephen Parker will step down from that role, both with immediate effect.

Ede-Golightly is currently chairman of DeepMatter Group PLC and Oxford Advanced Surfaces Ltd and a non-executive director at Oxehhealth Limited.

In a note to clients, analysts at 'house' broker Peel Hunt pointed out that today's announcements follow other recent changes to Silence's management and the board.

"As a reminder of other recent appointments at Silence, Rob Quinn was appointed CFO from his role as interim CFO (18th April) and Giles Campion was appointed (16th April) Head of R&D and Chief Medical Officer (previously SVP of R&D at Prosen and holding senior roles at Novartis and Albiomedix)," they said.

Peel Hunt continues to have its rating and target price for Silence 'under review'.

In afternoon trading, the shares were 4.3% higher at 73p.

Price: 148.5p

Market Cap: £107.25M

1 Year Share Price Graph



Share Information

Code: SLN

Listing: AIM

52 week High Low
175.00p 40.00p

Sector: Pharma & Biotech

Website: www.silence-therapeutics.com

Company Synopsis:

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

-- Adds analyst comment, share price --

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.